PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for form 1449/PTO 10/655,861 Application Number INFORMATION DISCLOSURE Filing Date September 5, 2003 STATEMENT BY APPLICANT First Named Inventor Yi Wang 1644 Art Unit (Use as many sheets as necessary) Examiner Name P. Gambel 2 ALXN-P01-102 Sheet of Attorney Docket Number

	U.S. PATENT DOCUMENTS						
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where		
Initials*	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
_							
_							
-							

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶		
		WO 95/29697	11-09-1995	Alexion Pharmaceuticals, Inc.				

Examiner	Date
Signature	Considered

"EXAMINER: Initial if reference considered, whether or not clation is in conformance with MPEP 609. Draw line through clation if not in conformance and not considered. Include copy of this form with next communication to applicant." Applicant's unique clation designation number (optional). See Kinds Codes of USPPO Patrick Draw (and the content of a production of the conformation of t Translation is attached.

PTOSBORE (7.09)
Approved for use through 07.41 2012. ONB 0851-2013
U.S. Patient and Traderiank Office; U.S. DEPARTMENT OF COMMERCE.
Under the Papervoih Reduction Act of 1965, no persons are required to respond to a collection of information unless a consistion and 100% control number.

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/655,861	
IN.	IFORMATIC	ON DIS	SCLOSURE	Filing Date	September 5, 2003	
STATEMENT BY APPLICANT				First Named Inventor	Yi Wang	
				Art Unit	1644	
	(Use as many sheets as necessary)			Examiner Name	P. Gambel	
Sheet	2	of	2	Attorney Docket Number	ALXN-P01-102	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, paget(s), volume-issue number(s), publisher, city and/or country where published.	T2
		Kaplan, Mariana, "Eculizumab," Current Opinion in Investigational Drugs, Vol. 3(7); pp. 1017-1023 (2002).	
		Moongkarndi et al., "Immunological and functional properties of two monoclonal antibodies against human C5," Immunobiol. Vol. 165, page 323 (1983).	
		Moongkarndi et al., "Monoclonal antibodies against the fifth component of human complement," Immunobiol, Vol 162; page 397 (1982).	
		Neurogen Reports Phase IIa Clinical Trial Results for Oral Asthma Drug, Press Release dated January 13, 2004.	
			\Box
			=

Exan Signa		Date Considered	
	(ER: Initial if reference considered, whether or not citation is in conformance with MPEP 609 add. Include copy of this form with next communication to applicant.	Draw line through cit	ation if not in conformance and not

^{&#}x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.